Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio

Lupin Pharmaceuticals has acquired Huminsulin, a portfolio of insulin products, from Eli Lilly, a move aimed at strengthening its position in the global diabetes care market. The acquisition will enhance Lupin’s product range, particularly in the insulin space, and allow the company to expand its reach to new geographies, especially in emerging markets. Huminsulin products are known for their affordability and effectiveness, making them a strong addition to Lupin’s diabetes portfolio. The deal aligns with Lupin's strategy of increasing its footprint in chronic disease management, particularly diabetes, and catering to the growing demand for insulin worldwide.